×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AVBP – arrivent biopharma, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AVBP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/6
08:03 am
avbp
ArriVent BioPharma (AVBP) had its price target raised by HC Wainwright from $42.00 to $44.00. They now have a "buy" rating on the stock.
Low
Report
ArriVent BioPharma (AVBP) had its price target raised by HC Wainwright from $42.00 to $44.00. They now have a "buy" rating on the stock.
3/5
04:31 pm
avbp
ArriVent BioPharma Reports Full Year 2025 Financial Results [Yahoo! Finance]
Low
Report
ArriVent BioPharma Reports Full Year 2025 Financial Results [Yahoo! Finance]
3/5
04:01 pm
avbp
ArriVent BioPharma Reports Full Year 2025 Financial Results
Medium
Report
ArriVent BioPharma Reports Full Year 2025 Financial Results
2/11
05:31 pm
avbp
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
Medium
Report
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
2/11
05:31 pm
avbp
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
Medium
Report
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
2/5
09:35 am
avbp
$207B Market Shift: The Race for Fast Track Approval in Oncology
Medium
Report
$207B Market Shift: The Race for Fast Track Approval in Oncology
1/23
05:06 am
avbp
ArriVent BioPharma (NASDAQ:AVBP) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
ArriVent BioPharma (NASDAQ:AVBP) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
1/12
10:35 am
avbp
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
Medium
Report
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/5
04:24 pm
avbp
Form S-8 ArriVent BioPharma, Inc.
Low
Report
Form S-8 ArriVent BioPharma, Inc.
3/5
04:18 pm
avbp
Form 10-K ArriVent BioPharma, Inc. For: Dec 31
Low
Report
Form 10-K ArriVent BioPharma, Inc. For: Dec 31
3/5
04:12 pm
avbp
Form 8-K ArriVent BioPharma, Inc. For: Mar 05
Low
Report
Form 8-K ArriVent BioPharma, Inc. For: Mar 05
3/5
06:09 am
avbp
Form SCHEDULE 13G/A ArriVent BioPharma, Inc. Filed by: Sofinnova Venture Partners IX, L.P.
Medium
Report
Form SCHEDULE 13G/A ArriVent BioPharma, Inc. Filed by: Sofinnova Venture Partners IX, L.P.
2/17
04:36 pm
avbp
Form SCHEDULE 13G/A ArriVent BioPharma, Inc. Filed by: INFINITUM ASSET MANAGEMENT, LLC
Low
Report
Form SCHEDULE 13G/A ArriVent BioPharma, Inc. Filed by: INFINITUM ASSET MANAGEMENT, LLC
2/17
09:01 am
avbp
Form SCHEDULE 13G/A ArriVent BioPharma, Inc. Filed by: HILLHOUSE INVESTMENT MANAGEMENT, LTD.
Low
Report
Form SCHEDULE 13G/A ArriVent BioPharma, Inc. Filed by: HILLHOUSE INVESTMENT MANAGEMENT, LTD.
2/4
08:44 pm
avbp
Form 4 ArriVent BioPharma, Inc. For: Feb 02 Filed by: LaChapelle Robin
Medium
Report
Form 4 ArriVent BioPharma, Inc. For: Feb 02 Filed by: LaChapelle Robin
2/4
08:43 pm
avbp
Form 4 ArriVent BioPharma, Inc. For: Feb 02 Filed by: Lutzker Stuart
Medium
Report
Form 4 ArriVent BioPharma, Inc. For: Feb 02 Filed by: Lutzker Stuart
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: